Table 2 Active clinical trials of proteasome inhibition in AML patients

From: The role of the proteasome in AML

Trial no.

Phase

Patients a

Intervention

NCT01861314

I

Poor-risk or r/r AML

Bortezomib Sorafenib Decitabine

NCT02312012

I

Relapsed AML/MDS post allogeneic HSCT

Bortezomib Lenalidomide

NCT02352558

I

Advanced or r/r hematologic malignancies (inc. AML)

Bortezomib Napabucasin (BBI608)

NCT01137747

I

R/r AML and ALL

Carfilzomib

NCT01534260

I/II

Complex, poor-risk, or FLT3-ITD+ AML

Bortezomib Vorinostat Sorafenib

NCT02419755

II

MLLb rearranged r/r hematologic malignancies (inc. AML), age ⩽21 years

Bortezomib Vorinostat

NCT01736943

II

R/r AML

Bortezomib Pegylated liposomal doxorubicin

NCT01420926

II

New AML, age ≥60 years

Bortezomib Decitabine

NCT01371981

III

New AML, age <30 years

Bortezomib Sorafenib

  1. aR/r, relapsed/refractory.
  2. bMLL, mixed-lineage leukemia.
Back to article page